search
Back to results

Autologous Cellular Graft in Surgical Treatment of Vitiligo

Primary Purpose

Vitiligo, Generalized

Status
Suspended
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
surgical treatment of vitiligo using NCES
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitiligo, Generalized focused on measuring stable resistant vitiligo, follicular cell suspension, Autologous cellular Micro-grafts, non cultured epidermal suspension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with non-segmental vitiligo (NSV) / segmental resistant lesions; with either 2 comparable lesions or large patches that can be divided
  • Stability for ≥ 1 year
  • Age >18 years
  • Lack of treatment for at least 1 month prior to surgery.

Exclusion Criteria:

  • -Vitiligo lesions responsive to conventional treatment modalities
  • Active vitiligo; new lesions, expansion of old lesions or koebnerization in < 1 year
  • Age < 18 years.
  • Keloidal tendency
  • Bleeding tendency
  • Pregnant females.

Sites / Locations

  • Cairo university hospitals, dermatology outpatient clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Autologous Cellular Micro-grafts suspension added to non cultured epidermal suspension (NCES)

Follicle cell suspension added t NCES

Non cultured epidermal suspension (NCES)

Arm Description

Under local anesthesia, a 2.5 mm punch biopsy will be used to extract 3 scalp tissue specimens from the patient's occiput behind the ear, using Rigeneracons medical device (CE certified class I; Human Brain Wave, Turin, Italy). The collected specimens will be placed in Rigeneracons by adding 1.5 mL of sterile physiologic solution to the device. The device then generates a cellular suspension by rotation of Rigeneracons at 80 RPM for 2 minutes. Subsequently, the obtained suspension is diluted with an additional 3 mL sterile physiologic solution. The resulting suspension will be added to NCES and placed on one of the derma braded vitiligo patches

• Under local anesthesia, 1 mm punch will be used to extract hair-follicles from occipital scalp behind the ear. Depending on the area to be transplanted, one hair follicle will be etracted for each 1 cm2. The extracted hair-follicles are washed with phosphate buffered saline (PBS) for about 3 times. The hair-follicles are then incubated with 0.25% trypsin - 0.05% ethylene diamine tetra acetic acid (EDTA) at 37°C for 90 min to prepare the single cell suspension. Within 15-20 min of incubation, the cells start loosening from each other. The hair-follicles are subsequently placed in another tube of trypsin and EDTA. At the end of three such cycles, a thin keratinous shaft is left behind. The cell suspensions of all the tubes are added in a single tube. The final cell pellet is obtained by centrifuging the combined cell suspension at 1000 rpm for 5 min. The resulting suspension will be added to NCES and placed on a comparable derma braded lesion

Melanocyte keratinocyte pellet will be prepared. Donor skin will be harvested from the gluteal region ; using a sterile shaving blade mounted on a Kocher's forceps. Cell Suspension will be prepared by placing the donor skin in 0.25% trypsin-EDTA (GIBCO) solution for 40 minutes at 37 ᴼC. sample and trypsin will be poured into a labelled petri dishes then neutralized using ringer's lactate. All the steps will be performed in a laminar air flow bench under strict aseptic conditions. The epidermis will be detached from the dermis which will be discarded. Then the epidermis will be cut into tiny pieces and scrapped so that no pigment is left on the surface. Afterwards, they will be transferred to sterile falcon tubes and centrifuged for 10 minutes at 1,000 rpm. The floating epidermal fragments and supernatant fluid will be removed, leaving the cell pellet containing epidermal cells rich in melanocytes and Keratinocytes at the bottom.

Outcomes

Primary Outcome Measures

comparing change in surface area in three arms
Percent change in surface area calculated by point counting technique will be compared between three arms

Secondary Outcome Measures

comparing percent of repigmentation in three arms
Percent change in lesional pigmentation as per VESTA score will be compared between three arms

Full Information

First Posted
August 14, 2022
Last Updated
January 21, 2023
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT05503368
Brief Title
Autologous Cellular Graft in Surgical Treatment of Vitiligo
Official Title
Autologous Cellular Micro-graft in Surgical Treatment of Stable Resistant Vitiligo: A Randomized Self-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Suspended
Why Stopped
lack of availability of the needed kits
Study Start Date
June 2023 (Anticipated)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a double blinded self controlled randomized trial to assess Autologous Micro Cellular Grafts in surgical treatment of stable resistant vitiligo. Given the stem cells, progenitor cells, and growth factors rich hair follicle based suspension resulting from Autologous Cellular Micro grafts (ACM), we aim at assessing the efficacy of ACM generated suspension in comparison to follicle cell suspension in surgical treatment of stable resistant vitiligo.
Detailed Description
Prior to surgery, two comparable lesions will be selected. Lesions will be assessed for: Surface Area using point counting technique. Any attempts of pigmentation using VESTA score. Lesions will be derma braded under local anesthesia using fractional laser CO2 resurfacing, Using dot mode off resurfacing will be performed at a power of 18-20 W, dwell time 1,000 milliseconds (DEKA, Florence, Italy). One to three passes will be performed until the epidermis is removed uniformly. Autologous Cellular Micrografts (ACM) suspension generated by regenera technique Under local anesthesia, a 2.5 mm punch biopsy will be used to extract 3 scalp tissue specimens from the patient's occiput behind the ear, using Rigeneracons medical device (CE certified class I; Human Brain Wave, Turin, Italy). The collected specimens will be placed in Rigeneracons by adding 1.5 mL of sterile physiologic solution to the device. The device then generates a cellular suspension by rotation of Rigeneracons at 80 RPM for 2 minutes. Subsequently, the obtained suspension is diluted with an additional 3 mL sterile physiologic solution. The resulting suspension will be added to melanocyte pellet generated by NCES technique and will be spread on one of the derma braded vitiliginous patches. Non cultured Epidermal Suspension (NCES): Melanocyte keratinocyte pellet will be prepared. Donor skin will be harvested from the gluteal region after anaesthetizing the area with intra-lesional Mepicaine L; using a sterile shaving blade mounted on a Kocher's forceps. An expansion ratio of 1:2 was used for each lesion separately to ensure equivalent melanocyte concentration in all transplanted lesions. Cell Suspension will be prepared by placing the donor skin in 0.25% trypsin-EDTA (GIBCO) solution for 40 minutes at 37 ᴼC. Each sample and trypsin will be poured into a labelled petri dishes then neutralized using ringer's lactate. All the steps will be performed in a laminar air flow bench under strict aseptic conditions. The epidermis will be detached from the dermis which will be discarded. Then the epidermis will be cut into tiny pieces and scrapped so that no pigment is left on the surface. Afterwards, they will be transferred to two labelled sterile falcon tubes and centrifuged for 10 minutes at 1,000 rpm. The floating epidermal fragments and supernatant fluid will be removed, leaving the cell pellet containing epidermal cells rich in melanocytes and Keratinocytes at the bottom. The resultant pellet will be suspended once in ACM generated by regenera technique, once in hair follicle suspension and once in 1 ml of ringer's lactate. Follicular Cellular Suspension: Under local anesthesia, 1 mm punch will be used to extract hair-follicles from occipital scalp behind the ear. Depending on the area to be transplanted, one pigmented follicles will be extracted for each 1 cm2. The extracted hair-follicles are washed with phosphate buffered saline (PBS) for about 3 times. The hair-follicles are then incubated with 0.25% trypsin - 0.05% ethylene diamine tetra acetic acid (EDTA) at 37°C for 60 min divided in to 3 intervals to prepare the single cell suspension. The first interval lasted 30 minutes after which the supernatant fluid containing separated cells was poured into a new falcon tube and neutralized by 1% fetal bovine serum. Fresh trypsin was then added to hair follicles and reincubated for 15 minutes twice. At the end of three such cycles, a thin keratinous shaft is left behind. The cell suspensions of all the tubes are added in a single tube. The final cell pellet is obtained by centrifuging the combined cell suspension at 1000 rpm for 5 min. The resulting suspension will be added to melanocyte pellet generated by NCES technique and will be spread on a comparable derma braded lesion. The resultant suspension will be checked for melanocyte count and viability using trypan blue dye exclusion method to ensure above 250 viable cells/mm2 of the recipient area prior to its spreading on the derma braded vitiligo patch. Both sites will be covered with a dry collagen sheet followed by sterile surgical pad and tegaderm. The area will be immobilized after bandaging and the patient will be advised to restrict movement at the operated site. Patients will start a 1-week course of antibiotics. Dressings will be removed after 1 week, and patients will receive excimer laser sessions, 3 sessions per week for 3 months. Patients will be followed up monthly for 3 months following the first visit at 1 week. At 3 months, both qualitative and quantitative assessment will be done. Qualitatively, blinded physician assessment of repigmentation as well as color match using serial photographs will be done. Quantitatively, point counting method as well as VESTA score will be used as well to assess degree of repigmentation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitiligo, Generalized
Keywords
stable resistant vitiligo, follicular cell suspension, Autologous cellular Micro-grafts, non cultured epidermal suspension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
self controlled study where 3 comparable lesions will be selected in each patient
Masking
Outcomes Assessor
Masking Description
The investigator doing the procedure is the only one who will know which side is assigned to which procedure, but the rest of the investigators including the ones assessing the outcome will be blinded
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Autologous Cellular Micro-grafts suspension added to non cultured epidermal suspension (NCES)
Arm Type
Experimental
Arm Description
Under local anesthesia, a 2.5 mm punch biopsy will be used to extract 3 scalp tissue specimens from the patient's occiput behind the ear, using Rigeneracons medical device (CE certified class I; Human Brain Wave, Turin, Italy). The collected specimens will be placed in Rigeneracons by adding 1.5 mL of sterile physiologic solution to the device. The device then generates a cellular suspension by rotation of Rigeneracons at 80 RPM for 2 minutes. Subsequently, the obtained suspension is diluted with an additional 3 mL sterile physiologic solution. The resulting suspension will be added to NCES and placed on one of the derma braded vitiligo patches
Arm Title
Follicle cell suspension added t NCES
Arm Type
Active Comparator
Arm Description
• Under local anesthesia, 1 mm punch will be used to extract hair-follicles from occipital scalp behind the ear. Depending on the area to be transplanted, one hair follicle will be etracted for each 1 cm2. The extracted hair-follicles are washed with phosphate buffered saline (PBS) for about 3 times. The hair-follicles are then incubated with 0.25% trypsin - 0.05% ethylene diamine tetra acetic acid (EDTA) at 37°C for 90 min to prepare the single cell suspension. Within 15-20 min of incubation, the cells start loosening from each other. The hair-follicles are subsequently placed in another tube of trypsin and EDTA. At the end of three such cycles, a thin keratinous shaft is left behind. The cell suspensions of all the tubes are added in a single tube. The final cell pellet is obtained by centrifuging the combined cell suspension at 1000 rpm for 5 min. The resulting suspension will be added to NCES and placed on a comparable derma braded lesion
Arm Title
Non cultured epidermal suspension (NCES)
Arm Type
Active Comparator
Arm Description
Melanocyte keratinocyte pellet will be prepared. Donor skin will be harvested from the gluteal region ; using a sterile shaving blade mounted on a Kocher's forceps. Cell Suspension will be prepared by placing the donor skin in 0.25% trypsin-EDTA (GIBCO) solution for 40 minutes at 37 ᴼC. sample and trypsin will be poured into a labelled petri dishes then neutralized using ringer's lactate. All the steps will be performed in a laminar air flow bench under strict aseptic conditions. The epidermis will be detached from the dermis which will be discarded. Then the epidermis will be cut into tiny pieces and scrapped so that no pigment is left on the surface. Afterwards, they will be transferred to sterile falcon tubes and centrifuged for 10 minutes at 1,000 rpm. The floating epidermal fragments and supernatant fluid will be removed, leaving the cell pellet containing epidermal cells rich in melanocytes and Keratinocytes at the bottom.
Intervention Type
Procedure
Intervention Name(s)
surgical treatment of vitiligo using NCES
Intervention Description
NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
Primary Outcome Measure Information:
Title
comparing change in surface area in three arms
Description
Percent change in surface area calculated by point counting technique will be compared between three arms
Time Frame
3 months follow up are required to assess response
Secondary Outcome Measure Information:
Title
comparing percent of repigmentation in three arms
Description
Percent change in lesional pigmentation as per VESTA score will be compared between three arms
Time Frame
3 months follow up are required to assess response

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with non-segmental vitiligo (NSV) / segmental resistant lesions; with either 2 comparable lesions or large patches that can be divided Stability for ≥ 1 year Age >18 years Lack of treatment for at least 1 month prior to surgery. Exclusion Criteria: -Vitiligo lesions responsive to conventional treatment modalities Active vitiligo; new lesions, expansion of old lesions or koebnerization in < 1 year Age < 18 years. Keloidal tendency Bleeding tendency Pregnant females.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rania M Mogawer
Organizational Affiliation
Kasr Alainy, Cairo University Hospitals
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Samia M Esmat
Organizational Affiliation
Kasr Alainy, Cairo University Hospitals
Official's Role
Study Director
Facility Information:
Facility Name
Cairo university hospitals, dermatology outpatient clinic
City
Cairo
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Participants' data that underlie reported results will be shared upon request, after deidentification
IPD Sharing Time Frame
Beginning 3 months and ending 12 months after article publication
IPD Sharing Access Criteria
Controlled Access: Researchers who provide a methodologically sound proposal will be allowed to access data to achieve aims in the approved proposal.
Citations:
PubMed Identifier
28157763
Citation
El-Zawahry BM, Esmat S, Bassiouny D, Zaki NS, Sobhi R, Saleh MA, Abdel-Halim D, Hegazy R, Gawdat H, Samir N, El-Hawary M, El Maadawi Z, Gouda H, Khorshied M. Effect of Procedural-Related Variables on Melanocyte-Keratinocyte Suspension Transplantation in Nonsegmental Stable Vitiligo: A Clinical and Immunocytochemical Study. Dermatol Surg. 2017 Feb;43(2):226-235. doi: 10.1097/DSS.0000000000000962.
Results Reference
result
PubMed Identifier
31643084
Citation
Ruiz RG, Rosell JMC, Ceccarelli G, De Sio C, De Angelis GC, Pinto H, Astarita C, Graziano A. Progenitor-cell-enriched micrografts as a novel option for the management of androgenetic alopecia. J Cell Physiol. 2020 May;235(5):4587-4593. doi: 10.1002/jcp.29335. Epub 2019 Oct 23.
Results Reference
result
PubMed Identifier
34824538
Citation
Zari S. Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A Retrospective Cohort Study. Clin Cosmet Investig Dermatol. 2021 Nov 19;14:1725-1736. doi: 10.2147/CCID.S334807. eCollection 2021.
Results Reference
result
PubMed Identifier
29387874
Citation
Razmi T M, Kumar R, Rani S, Kumaran SM, Tanwar S, Parsad D. Combination of Follicular and Epidermal Cell Suspension as a Novel Surgical Approach in Difficult-to-Treat Vitiligo: A Randomized Clinical Trial. JAMA Dermatol. 2018 Mar 1;154(3):301-308. doi: 10.1001/jamadermatol.2017.5795.
Results Reference
result
PubMed Identifier
30601885
Citation
Thakur V, Kumar S, Kumaran MS, Kaushik H, Srivastava N, Parsad D. Efficacy of Transplantation of Combination of Noncultured Dermal and Epidermal Cell Suspension vs Epidermal Cell Suspension Alone in Vitiligo: A Randomized Clinical Trial. JAMA Dermatol. 2019 Feb 1;155(2):204-210. doi: 10.1001/jamadermatol.2018.4919.
Results Reference
result
PubMed Identifier
21275943
Citation
Mohanty S, Kumar A, Dhawan J, Sreenivas V, Gupta S. Noncultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo. Br J Dermatol. 2011 Jun;164(6):1241-6. doi: 10.1111/j.1365-2133.2011.10234.x.
Results Reference
result
PubMed Identifier
15149497
Citation
Gho CG, Braun JE, Tilli CM, Neumann HA, Ramaekers FC. Human follicular stem cells: their presence in plucked hair and follicular cell culture. Br J Dermatol. 2004 May;150(5):860-8. doi: 10.1111/j.1365-2133.2004.05862.x.
Results Reference
result

Learn more about this trial

Autologous Cellular Graft in Surgical Treatment of Vitiligo

We'll reach out to this number within 24 hrs